^
Association details:
| Biomarker: | MAP2K2 L46F |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
The MEK2V35M, MEK2L46F, and MEK2N126D mutants also engendered resistance to RAF and MEK inhibition, although their effect were not as pronounced as those of MEK2C125S.
DOI:
10.1158/2159-8290.CD-13-0617
